Achilles Therapeutics develops precision T cell therapies that target clonal neoantigens, unique protein markers present on cancer cells but absent from healthy tissue. This approach enables the targeted destruction of all cancer cells while preserving normal cells, addressing the challenge of tumor heterogeneity in cancer treatment.
Funding
$331.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors exhibit significant heterogeneity, meaning cancer cells within the same tumor can possess different genetic mutations. This intratumoral heterogeneity poses a challenge for traditional cancer therapies, as treatments targeting only certain mutations may leave other cancer cells unaffected, leading to relapse and treatment resistance.
Solution
Achilles Therapeutics develops personalized T cell therapies that target clonal neoantigens, which are unique protein markers found on the surface of cancer cells but not on healthy cells. These clonal neoantigens arise early in cancer development and are present across all cancer cells within a tumor, regardless of heterogeneity. By targeting these markers, Achilles' T cell therapies aim to selectively destroy all cancer cells while sparing healthy tissue, offering a potential solution to overcome tumor heterogeneity and improve treatment outcomes. The company leverages a bioinformatics platform, powered by AI, to identify these clonal neoantigens.
Target Audience
The primary target audience includes patients with solid tumors who have relapsed or are resistant to standard therapies, as well as oncologists and researchers seeking more effective and personalized cancer treatment options.
Features
- Personalized T cell therapies targeting clonal neoantigens
- AI-powered bioinformatics platform for neoantigen identification
- Selective destruction of cancer cells while preserving healthy tissue
- Addresses the challenge of tumor heterogeneity in solid tumors
- Aims to improve treatment outcomes and reduce relapse rates